A flexible approach to
Alzheimer’s Disease
Clinical Trials
QPS has excellent connections with leading AD researchers, and can therefore support site selection that guarantees the highest quality investigators and efficient patient recruitment and retention.

QPS has a longstanding history of conducting trials in neurodegenerative disorders such as Alzheimer’s disease (AD). Our clinical team is specialized and focused on AD treatment development. The team consists of medical, regulatory and operational experts with significant experience in AD study planning and conduct. Our clinicians are aware of the latest diagnostic criteria, and the most recent developments in study design, to meet the requirements of modern AD research. We have performed trials in Phase I, Phase II and Phase III, and we have nearly 3,000 potential AD study subjects in our our database.

QPS Regulatory Affairs successfully supports study start up, while offering strategic advice on regulatory pathways and possibilities. In addition, we provide direct access to, and organize/chair meetings with relevant contact persons at Regulatory Agencies. Whether you are planning a clinical trial of small molecules, biologics, immunotherapies or medical devices, QPS has the experience and resources to handle your study and deliver high quality data on time and within the planned budget.
QPS’ Experience in AD Clinical Development

**TRIAL EXPERIENCE**

- Study Design of **16** Trials
- Regulatory Affairs in **21** Trials
- Monitoring in **26** Trials
- Safety in **15** Trials
- Data Management in **18** Trials
- Project Management in **21** Trials
- Site Selection in **21** Trials
- Medical Writing in **21** Trials
- Statistics in **21** Trials
Time is of the essence in drug development. Contact the QPS business development team today!

CALL +1 512 350 2827
EMAIL infobd@qps.com

QPS is a Global CRO with locations around the world to serve the evolving needs of the Pharmaceutical and Biotech industries.